Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02584413 · ClinicalTrials.gov registry record · NA
Hypotonia and Neurofibromatosis Type 1 (NF1) Glioma
A NA study, sponsored by Washington University School of Medicine.
- Terminated
- Registry status
- NA
- Development phase
- 29
- Enrollment target
NCT02584413 is a NA study that was terminated before completion, run by Washington University School of Medicine. The registered enrollment target is 29 participants.
The verdict
NCT02584413, a NA study, was terminated before completion, sponsored by Washington University School of Medicine.
- TERMINATED
- Registry status
- NA
- Development phase
- 29 participants
- Enrollment target
Study Summary
Currently, optic pathway gliomas (OPG) are detected based on abnormal findings made during annual ophthalmologic exams. However, because these exams are annual, it is possible for healthcare providers to miss the point at which a child's vision begins to decline (potentially indicating an OPG). If at-risk children are screened for hypotonia early in life, those children who are hypotonic may undergo magnetic resonance imaging (MRI) to evaluate for OPG before they are showing ophthalmologic symptoms. This would enable healthcare providers to discover vision loss earlier and treat symptomatic OPGs earlier, thereby allowing us a better chance of preventing further vision loss in children with OPGs.
Interventions
- DEVICE Magnetic resonance imaging
- DRUG Gadolinium contrast
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2013-04-16 |
| Est. Completion | 2019-02-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02584413
The ClinicalTrials.gov registry entry for NCT02584413 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Magnetic resonance imaging is the first listed.
NCT02584413 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02584413 about?
NCT02584413 is a clinical study titled "Hypotonia and Neurofibromatosis Type 1 (NF1) Glioma". Currently, optic pathway gliomas (OPG) are detected based on abnormal findings made during annual ophthalmologic exams. However, because these exams are annual, it is possible for healthcare providers to miss the point at which a child's vision begins to decline (potentially indicating an OPG). If a...
What is the current status of trial NCT02584413?
This trial is currently terminated. It is a NA study. The enrollment target is 29 participants. The study started on 2013-04-16. Estimated completion is 2019-02-07.
What interventions are being tested in trial NCT02584413?
The interventions under investigation include: Magnetic resonance imaging (DEVICE), Gadolinium contrast (DRUG).
Who is sponsoring clinical trial NCT02584413?
This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.